Development of LpxH Inhibitors Chelating the Active Site Dimanganese Metal Cluster of LpxH.

ABSTRACT: Despite the widespread emergence of multidrug-resistant nosocomial Gram-negative bacterial infections and the major public health threat it brings, no new class of antibiotics for Gram-negative pathogens has been approved over the past five decades. Therefore, there is an urgent medical need for developing effective novel antibiotics against multidrug-resistant Gram-negative pathogens by targeting previously unexploited pathways in these bacteria. To fulfill this crucial need, we have been investigating a series of sulfonyl piperazine compounds targeting LpxH, a dimanganese-containing UDP-2,3-diacylglucosamine hydrolase in the lipid A biosynthetic pathway, as novel antibiotics against clinically important Gram-negative pathogens. Inspired by a detailed structural analysis of our previous L

SUBMITTER: Kwak SH 

PROVIDER: S-EPMC10239344 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature